A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii

Shajila Siricilla, Katsuhiko Mitachi, Junshu Yang, Shakiba Eslamimehr, Maddie R. Lemieux, Bernd Meibohm, Yinduo Ji, Michio Kurosu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 μg/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 μg/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 μg/mL and an MDR A. baumannii with the MBC of 3.13 μg/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected C57BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.

Original languageEnglish (US)
Pages (from-to)2869-2878
Number of pages10
JournalJournal of Medicinal Chemistry
Volume60
Issue number7
DOIs
StatePublished - Apr 13 2017

Fingerprint

Acinetobacter baumannii
Doxycycline
Pharmaceutical Preparations
Colistin
Tobramycin
Acinetobacter
Gram-Negative Bacteria
Inbred C57BL Mouse
Sepsis
pleuromutilin
Infection

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Drug Discovery

Cite this

A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. / Siricilla, Shajila; Mitachi, Katsuhiko; Yang, Junshu; Eslamimehr, Shakiba; Lemieux, Maddie R.; Meibohm, Bernd; Ji, Yinduo; Kurosu, Michio.

In: Journal of Medicinal Chemistry, Vol. 60, No. 7, 13.04.2017, p. 2869-2878.

Research output: Contribution to journalArticle

Siricilla, Shajila ; Mitachi, Katsuhiko ; Yang, Junshu ; Eslamimehr, Shakiba ; Lemieux, Maddie R. ; Meibohm, Bernd ; Ji, Yinduo ; Kurosu, Michio. / A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii. In: Journal of Medicinal Chemistry. 2017 ; Vol. 60, No. 7. pp. 2869-2878.
@article{fbcc1c3cc4e74216b04d134ae02c45b4,
title = "A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii",
abstract = "Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 μg/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 μg/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 μg/mL and an MDR A. baumannii with the MBC of 3.13 μg/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected C57BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.",
author = "Shajila Siricilla and Katsuhiko Mitachi and Junshu Yang and Shakiba Eslamimehr and Lemieux, {Maddie R.} and Bernd Meibohm and Yinduo Ji and Michio Kurosu",
year = "2017",
month = "4",
day = "13",
doi = "10.1021/acs.jmedchem.6b01805",
language = "English (US)",
volume = "60",
pages = "2869--2878",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "7",

}

TY - JOUR

T1 - A New Combination of a Pleuromutilin Derivative and Doxycycline for Treatment of Multidrug-Resistant Acinetobacter baumannii

AU - Siricilla, Shajila

AU - Mitachi, Katsuhiko

AU - Yang, Junshu

AU - Eslamimehr, Shakiba

AU - Lemieux, Maddie R.

AU - Meibohm, Bernd

AU - Ji, Yinduo

AU - Kurosu, Michio

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 μg/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 μg/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 μg/mL and an MDR A. baumannii with the MBC of 3.13 μg/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected C57BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.

AB - Multidrug-resistant (MDR) Acinetobacter baumannii is one of the most difficult Gram-negative bacteria to treat and eradicate. In a cell-based screening of pleuromutilin derivatives against a drug sensitive A. baumannii strain, new molecules (2-4) exhibit bacteriostatic activity with 3.13 μg/mL concentration and 1 shows bactericidal activity with an MBC of 6.25 μg/mL. The pleuromutilin derivative 1 displays strong synergistic effects with doxycycline in a wide range of concentrations. A 35/1 ratio of 1 and doxycycline (1-Dox 35/1) kills drug susceptible A. baumannii with the MBC of 2.0 μg/mL and an MDR A. baumannii with the MBC of 3.13 μg/mL. In vitro anti-Acinetobacter activity of 1-Dox 35/1 is superior to that of clinical drugs such as tobramycin, tigecycline, and colistin. The efficacy of 1-Dox 35/1 is evaluated in a mouse septicemia model; treatment of the infected C57BL/6 mice with 1-Dox 35/1 protects from lethal infection of A. baumannii with an ED50 value of <2.0 mg/kg.

UR - http://www.scopus.com/inward/record.url?scp=85017550129&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017550129&partnerID=8YFLogxK

U2 - 10.1021/acs.jmedchem.6b01805

DO - 10.1021/acs.jmedchem.6b01805

M3 - Article

VL - 60

SP - 2869

EP - 2878

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 7

ER -